AbbVie, a drug company based in North Chicago, Illinois, is paying $200 million to acquire Madison-based Nimble Therapeutics, which is developing an oral therapy that could treat psoriasis and ...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...

The deal includes a $200m cash payment from AbbVie at closing, subject to standard adjustments, alongside potential interim funding payments. Credit: © AbbVie Inc ...

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of ...

In an at­tempt to con­tin­ue its I&I dom­i­nance be­yond Hu­mi­ra, Skyrizi and Rin­voq, Ab­b­Vie is buy­ing up an­oth­er small au­toim­mune start­up.

AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.

North Chicago-based AbbVie announced today that it plans to buy Nimble Therapeutics and its promising drug designed to treat psoriasis and inflammatory bowel disease. Nimble also has a pipeline of ...

(RTTNews) - AbbVie Inc. (ABBV), Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along with certain interim funding and milestone payments.

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across ...